SN 38, DNA topoisomerase I inhibitor (ab141108)
Key features and details
- DNA topoisomerase I inhibitor. Active metabolite of CPT-11.
- CAS Number: 86639-52-3
- Purity: > 99%
- Soluble in DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
製品の概要
-
製品名
SN 38, DNA topoisomerase I inhibitor -
製品の詳細
DNA topoisomerase I inhibitor. Active metabolite of CPT-11. -
別名
- 7-Ethyl-10-hydroxycamptothecin
-
生理活性の詳細
Active metabolite of CPT-11 (Irinotecan) (ab141107). Inhibits DNA topoisomerase I (IC50 values are 0.74 and 1.9 μM in P388 and Ehrlich cells respectively) and DNA and RNA synthesis (IC50 values are 77 nM and 1.3 μM respectively). Shows potent antitumor activity, causes S- and G2 cell cycle arrest and induces apoptosis. Active in vivo.
-
精製度
> 99% -
CAS 番号
86639-52-3 -
構造式
製品の特性
-
体系名
(4S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione -
分子量
392.41 -
分子式
C22H20N2O5 -
PubChem 登録番号
104842 -
保存方法
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解性
Soluble in DMSO to 100 mM -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
CC[C@]1(O)C=2C=C3c4nc5ccc(O)cc5c(CC)c4CN3C(=O)C=2COC1=O -
由来
Synthetic
-
研究分野
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab141108の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
Functional Studies |
Use at an assay dependent concentration.
|
特記事項 |
---|
Functional Studies
Use at an assay dependent concentration. |
画像
-
2D chemical structure image of ab141108, SN 38, DNA topoisomerase I inhibitor
-
ab2893 staining γH2A.X in HeLa cells treated with SN 38 (ab141108), by ICC/IF. Increase of γH2A.X nuclear expression correlates with increased concentration of SN 38, as described in literature.
The cells were incubated at 37°C for 6 hours in media containing different concentrations of ab141108 (SN 38) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab2893 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (4)
ab141108 は 4 報の論文で使用されています。
- Tsai CL et al. Topoisomerase I Inhibition Radiosensitizing Hepatocellular Carcinoma by RNF144A-mediated DNA-PKcs Ubiquitination and Natural Killer Cell Cytotoxicity. J Clin Transl Hepatol 11:614-625 (2023). PubMed: 36969901
- Amin N et al. TP5: A Novel Therapeutic Approach Targeting Aberrant and Hyperactive CDK5/p25 for the Treatment of Colorectal Carcinoma. Int J Mol Sci 24:N/A (2023). PubMed: 37511490
- Winkler C et al. SLFN11 informs on standard of care and novel treatments in a wide range of cancer models. Br J Cancer 124:951-962 (2021). PubMed: 33339894
- Peter S et al. Cell-based high-throughput compound screening reveals functional interaction between oncofetal HMGA2 and topoisomerase I. Nucleic Acids Res N/A:N/A (2016). PubMed: 27587582